IGF2BP3 and acute myeloid leukemia: Next, we explored the direct regulatory mechanisms of SENP1 upstream and downstream using in vivo and in vitro AML models, and proposed that SENP1 is driven by IGF2BP3 in m6A mode and activates AKT signaling via HDAC2 to promote AML progression (Fig. 8G).